Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
recreational drug |
| gptkbp:CASNumber |
42542-10-9
|
| gptkbp:chirality |
R-enantiomer
|
| gptkbp:developedBy |
MAPS Public Benefit Corporation
|
| gptkbp:hasEnantiomer |
R-enantiomer of MDMA
|
| gptkbp:hasMolecularFormula |
C11H15NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
MM-402 (R-MDMA)
|
| gptkbp:investigatedBy |
gptkb:autism_spectrum_disorder
psychiatric disorders |
| gptkbp:isomerOf |
gptkb:MDMA
|
| gptkbp:IUPACName |
(R)-1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
|
| gptkbp:legalStatus |
investigational drug
|
| gptkbp:molecularWeight |
193.24 g/mol
|
| gptkbp:pharmacological_effect |
entactogen
stimulant empathogen |
| gptkbp:relatedTo |
S-MDMA
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
R-(+)-MDMA
R-MDMA |
| gptkbp:bfsParent |
gptkb:Mind_Medicine
|
| gptkbp:bfsLayer |
7
|